Quantitative assessment of minimal residual disease for monitoring of paediatric patients with relapsed/refractory anaplastic large‐cell lymphoma treated with brentuximab vedotin: A case series.

MLA

Contarini, Giorgia, et al. “Quantitative Assessment of Minimal Residual Disease for Monitoring of Paediatric Patients with Relapsed/Refractory Anaplastic Large‐cell Lymphoma Treated with Brentuximab Vedotin: A Case Series.” British Journal of Haematology, vol. 204, no. 1, Jan. 2024, pp. 352–55. EBSCOhost, https://doi.org/10.1111/bjh.19151.

APA

Contarini, G., Carraro, E., Lovisa, F., Martire, G., Lo, N. L., Sala, A., Pillon, M., & Mussolin, L. (2024). Quantitative assessment of minimal residual disease for monitoring of paediatric patients with relapsed/refractory anaplastic large‐cell lymphoma treated with brentuximab vedotin: A case series. British Journal of Haematology, 204(1), 352–355. https://doi.org/10.1111/bjh.19151

Chicago

Contarini, Giorgia, Elisa Carraro, Federica Lovisa, Gaia Martire, Nigro, Luca Lo, Alessandra Sala, Marta Pillon, and Lara Mussolin. 2024. “Quantitative Assessment of Minimal Residual Disease for Monitoring of Paediatric Patients with Relapsed/Refractory Anaplastic Large‐cell Lymphoma Treated with Brentuximab Vedotin: A Case Series.” British Journal of Haematology 204 (1): 352–55. doi:10.1111/bjh.19151.